Clinical trials: Autoimmune Disease
Multiple Sclerosis
Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
This study is to find out if there is any benefit to adding Simvastatin to Interferon-beta-1a in patients with Multiple Sclerosis.
- Trial name
- SIMCOMBIN (NCT00492765)
- Testing
- Interferon-beta-1a, Simvastatin
- Where
- Denmark
- Volunteers
- 380 people
- Sponsor
- Biogen
Rheumatoid Arthritis
AZD5672 Bioavailability Study in Healthy Male and Female Subjects
The aim of this study is to compare the blood levels achieved with a new formulation of AZD5672 to an existing formulation of AZD5672 used in previous studies
- Trial name
- NCT00871767
- Testing
- AZD5672
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Pain
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects
The purpose of this study is to evaluate the effectiveness, tolerability, and safety of oxymorphone immediate release (IR) oral liquid as an analgesic in pediatric subjects having severe to moderate chronic pain.
- Trial name
- NCT01206907
- Testing
- oxymorphone IR
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Relapsing-Remitting Multiple Sclerosis
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
The primary objective of the study is to evaluate the impact of early treatment with Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) participants on their quality of life (QoL) as measured by Multiple Sclerosis Impact…
- Trial name
- COSTAN (NCT01706107)
- Where
- 11 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Biogen
Primary Progressive Multiple Sclerosis
This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.
The purpose of this study is to evaluate whether FTY720 is effective in delaying MS disability progression compared to placebo in patients with PPMS.
- Trial name
- INFORMS (NCT00731692)
- Testing
- FTY720
- Where
- 157 sites in United States, Australia and 16 more
- Volunteers
- 970 people
- Sponsor
- Novartis Pharmaceuticals
NMOSD, Neuromyelitis Optica Spectrum Disorders
Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
The primary objective of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Eculizumab in Chinese Adults with Neuromyelitis Optica Spectrum Disorders (NMOSD).
- Trial name
- ECU-NMO-304 (NCT06724809)
- Testing
- eculizumab
- Where
- 7 sites in China
- Volunteers
- 21 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Immunoglobulin A Nephropathy
A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe
The purpose of this study is to evaluate participant treatment experience with Povetacicept injection administered via autoinjector relative to Sibeprenlimab injection administered via prefilled syringe (PFS), and to assess the…
- Trial name
- NCT07890909
- Testing
- Povetacicept, Sibeprenlimab
- Volunteers
- 40 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Systemic Lupus Erythematosus
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender
A study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and repeat doses of 800 mg GSK2586184 in healthy subjects.
- Trial name
- JAK116439 (NCT01687309)
- Testing
- GSK2586184 800mg single and repeat dose, GSK2586184 single dose taken with food, GSK2586184 single dose taken without food
- Where
- Belgium
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 1
A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes
The study is done to compare how faster aspart is taken up, broken down and removed from the body between different age groups (children [6-11 years], adolescents [12-17 years] and adults [18-64 years]) who have diabetes.
- Trial name
- NCT03407599
- Testing
- Faster aspart, Insulin aspart (NovoRapid®)
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus
Primary Objective: To compare the pharmacokinetic (PK) characteristics of single doses of insulin glargine given as U200 and U500 with those of a single dose (SD) of Lantus® U100 in a euglycemic clamp setting in subjects with…
- Trial name
- NCT02201199
- Testing
- insulin glargine U200 HOE901, insulin glargine U500 HOE901, insulin glargine U100 HOE901
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Sanofi
Immune Thrombocytopenic Purpura
Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training
Cross-sectional study, observation made by healthcare professionals of subjects or caregivers, administering romiplostim at their first standard-of-care visit 4 weeks after training with the home administration training pack.
- Trial name
- NCT02085993
- Where
- 22 sites in Austria, Belgium and 6 more
- Volunteers
- 41 people
- Sponsor
- Amgen
Rheumatoid Arthritis (RA)
Probiotics in Adults With Rheumatoid Arthritis
The goal of this clinical study is to collect data on the effect of probiotic administration on clinical outcomes in rheumatoid arthritis patients.
- Trial name
- NCT07304505
- Testing
- Align Extra Strength Probiotic Supplement
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ancilia Biosciences
Multiple Sclerosis (MS)
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
This trial is being conducted to demonstrate the efficacy of nabiximols, compared with placebo, when added to standard of care, in the treatment of muscle spasms associated with multiple sclerosis (MS).
- Trial name
- RELEASE MSS3 (NCT04203498)
- Testing
- Nabiximols
- Where
- 37 sites in United States, Czechia and 3 more
- Volunteers
- 139 people
- Sponsor
- Jazz Pharmaceuticals
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis
This is a phase 2, double-blind, randomized, controlled, multicenter trial evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of 2 VIS954 dosing regimens in patients with moderate to severe acute…
- Trial name
- NCT07904806
- Testing
- VIS954, Standard Of Care (SOC)
- Volunteers
- 75 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Rheumatoid Arthritis
Post-marketing Observational Study in Subjects With Rheumatoid Arthritis
The purpose of this observational study was to observe and assess the long term use, safety, and effectiveness of adalimumab in a normal clinical setting.
- Trial name
- ReAlise (NCT00234884)
- Testing
- adalimumab
- Where
- 311 sites in Australia, Austria and 9 more
- Volunteers
- 3,435 people
- Sponsor
- Abbott
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) and the pharmacokinetic (exposure of the trial drug in the body) properties of…
- Trial name
- NCT01773798
- Testing
- insulin degludec/insulin aspart 15, insulin degludec/insulin aspart, insulin degludec
- Where
- Austria
- Volunteers
- 33 people
- Sponsor
- Novo Nordisk A/S
Arthritis, Rheumatoid
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory…
- Trial name
- NCT07412704
- Testing
- BMS-986528
- Where
- 39 sites in United States, Belgium and 9 more
- Volunteers
- 84 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Study of NI-071 in Comparison With Remicade in Patients With Rheumatoid Arthritis
The purpose of this study is to compare the safety of NI-071 with Remicade® (infliximab) in patients with Rheumatoid Arthritis inadequately treated with Methotrexate.
- Trial name
- NCT01567358
- Testing
- Infliximab
- Where
- Japan
- Volunteers
- 14 people
- Sponsor
- Nichi-Iko Pharmaceutical Co., Ltd.
Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
This is a multi-country, prospective safety study of pregnant women exposed to efgartigimod or efgartigimod PH20 SC any time within 25 days prior to conception or any time during pregnancy.
- Trial name
- NCT06299748
- Testing
- Efgartigimod
- Where
- 4 sites in United States, Germany and 2 more
- Volunteers
- 279 people
- Sponsor
- argenx
Idiopathic Inflammatory Myopathies(IIM), Immune Thrombocytopenia(ITP)
An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
This is a single arm, open-label, dose escalation and expansion study to evaluate the safety, tolerability and preliminary efficacy of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA(BZE2204) in…
- Conditions
- Idiopathic Inflammatory Myopathies(IIM), Immune Thrombocytopenia(ITP), Systemic Lupus Erythematosus(SLE)
- Trial name
- NCT07174843
- Testing
- CD19/CD22/BCMA CAR-T cells(BZE2204)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd